The store will not work correctly when cookies are disabled.
N-(1H-pyrazolo[4,3-b]pyridin-3-yl)quinazolin-6-amine
ID: ALA4753444
PubChem CID: 162653705
Max Phase: Preclinical
Molecular Formula: C14H10N6
Molecular Weight: 262.28
Molecule Type: Unknown
Associated Items:
Names and Identifiers
Canonical SMILES: c1cnc2c(Nc3ccc4ncncc4c3)n[nH]c2c1
Standard InChI: InChI=1S/C14H10N6/c1-2-12-13(16-5-1)14(20-19-12)18-10-3-4-11-9(6-10)7-15-8-17-11/h1-8H,(H2,18,19,20)
Standard InChI Key: ZCYXXLHBMZVEQJ-UHFFFAOYSA-N
Molfile:
RDKit 2D
20 23 0 0 0 0 0 0 0 0999 V2000
26.2065 -18.5519 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2053 -19.3714 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.9134 -19.7804 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.6230 -19.3709 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.9116 -18.1430 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.6236 -18.5496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.2304 -17.9981 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.8934 -17.2505 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.0784 -17.3402 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.0305 -18.1643 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.5745 -17.5544 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.3740 -17.7220 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.8570 -16.1716 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.3167 -16.7819 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.6618 -16.3360 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.9137 -17.1109 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.7090 -17.2788 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2533 -16.6728 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.9966 -15.8962 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.2019 -15.7320 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 6 1 0
5 1 1 0
5 6 2 0
6 7 1 0
7 8 2 0
8 9 1 0
9 5 1 0
7 10 1 0
10 11 1 0
11 12 2 0
12 16 1 0
15 13 1 0
13 14 2 0
14 11 1 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 20 1 0
20 15 2 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 262.28 | Molecular Weight (Monoisotopic): 262.0967 | AlogP: 2.64 | #Rotatable Bonds: 2 |
Polar Surface Area: 79.38 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 12.90 | CX Basic pKa: 2.97 | CX LogP: 1.95 | CX LogD: 1.95 |
Aromatic Rings: 4 | Heavy Atoms: 20 | QED Weighted: 0.58 | Np Likeness Score: -1.70 |
References
1. Panarese JD,Engers DW,Wu YJ,Guernon JM,Chun A,Gregro AR,Bender AM,Capstick RA,Wieting JM,Bronson JJ,Macor JE,Westphal R,Soars M,Engers JE,Felts AS,Rodriguez AL,Emmitte KA,Jones CK,Blobaum AL,Conn PJ,Niswender CM,Hopkins CR,Lindsley CW. (2019) The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate., 29 (2.0): [PMID:30503632] [10.1016/j.bmcl.2018.10.050] |